Clarification
Thanks to our loyal readers wanted to clarify something from today’s post entitled “A Leg Up”. In that post we noted that we could not find any ongoing CV studies for either Invokana or Fraxiga. As it turns out we were incorrect and there are two ongoing studies. First there the CANVAS and CANVAS-R trials for Invokana which are scheduled to be completed in 2017. Plus there is the DECLARE TIMI-59 Fraxiga which has an estimated completion date of 2019.
It seems that when we searched www.clincialtrials.gov we were not specific enough with our search terms.
Even with these new facts we believe that Lilly (NYSE:LLY) still has a leg up on the competition as it won’t be until 2017 until we know whether the competition has replicated the results Lilly has seen. The burden of expectations has fallen squarely on the shoulders of Johnson and Johnson (NYSE:JNJ) and AstraZeneca (NYSE:AZN).
We regret our error and in the future will be more specific when searching for information on the site.
